^
Association details:
| Biomarker: | ER positive |
|---|---|
| Cancer: | Estrogen Receptor Positive Breast Cancer |
| Drug Class: | CDK4 inhibitor + CDK6 inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
The role of CDK4/6 inhibitors in older and younger patients with breast cancer: A systematic review and meta-analysis
Published date:
05/12/2023
Excerpt:
This large, pooled analysis is the first to demonstrate that CDK4/6 inhibitors confer OS and PFS benefits in elderly patients (those aged ≥65 years) with advanced ER + BC...For PFS analysis, data of PALOMA-2, MONALEESA-2, MONARCH-2 and 3, outcome informations were available for patients aged ≥75 years (pooled HR = 0.53; 95% CI 0.48–0.58) and favored CDK 4/6 + ET arms.
DOI:
10.1016/j.breast.2023.05.002
Source:
Title:
HSR22-163: Real World Data and Independent Predictors of Clinical Outcomes with CDK Inhibitors in Metastatic ER+ Breast Cancer Patients
Published date:
03/31/2022
Excerpt:
A retrospective review was performed in 269 patients with HR+ MBC treated with a CDKI….Median PFS and OS for the entire cohort were 21.5 months and 57.6 months, respectively. 84.1% of patients with bone-only disease were alive at 60 months compared to 41.8% in patients with mixed bony and visceral metastases (p=0.004)....In our study, patients treated with CDKIs had observed median OS/PFS comparable to those reported in clinical trials, thus further supporting their use in a real-world population.
DOI:
https://doi.org/10.6004/jnccn.2021.7163